16 FDCs Prohibited in India: Partner with Walter Healthcare for Compliance
- Akshay Gautam
- Jun 27
- 12 min read
Understand the latest regulatory changes, explore the affected Fixed Dose Combinations, and learn how Walter Healthcare helps pharmaceutical companies stay compliant, market-ready, and future-focused.
Introduction
In the high-stakes world of pharmaceutical manufacturing, patient safety is more than a regulatory requirement; it is the bedrock of industry trust. As clinical data matures and post-marketing surveillance unearths new evidence, global regulators are increasingly tightening the leash on Fixed Dose Combinations (FDCs). While these products offer clear therapeutic convenience, they are now under intense scrutiny to eliminate irrational pairings that compromise patient well-being for commercial gain.
This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.
This blog provides insight about:
What are Fixed Dose Combinations?
Why were these 16 FDCs prohibited?
Which products are affected?
What does Section 26A empower the Government to do?
What are the implications for pharmaceutical companies?
How should manufacturers respond?
Why does choosing a regulatory-focused manufacturing partner matter more than ever?
Understanding Fixed Dose Combinations (FDCs)
An FDC integrates two or more active pharmaceutical ingredients (APIs) into a single delivery system. When engineered with clinical precision, these formulations are game-changers for therapeutic adherence.
When scientifically justified, FDCs provide numerous advantages:
Improved patient compliance
Reduced pill burden
Better therapeutic outcomes
Simplified treatment regimens
Lower healthcare costs
Enhanced adherence for chronic diseases
From managing hypertension to streamlining HIV regimens, rational FDCs reduce pill burden and lower overall healthcare costs. However, the regulatory threshold for "rationality" is higher than ever.
Anti-hypertensive combinations
Anti-diabetic combinations
Anti-tuberculosis therapy
HIV treatment combinations
Combination antibiotics
However, not every combination qualifies as rational.
A combination is deemed "irrational" if it fails to prove additive efficacy or if the secondary API introduces unnecessary risks like antimicrobial resistance or complex adverse reactions. India's evaluation process is now designed to filter out these clinical redundancies.
Provide no additional therapeutic benefit
Increase adverse drug reactions
Promote antimicrobial resistance
Lead to unnecessary exposure to medicines
Complicate dosing adjustments
Increase treatment costs
This is precisely why India maintains one of the world's most rigorous evaluation systems for Fixed Dose Combinations.
The Regulatory Announcement: What Has Been Prohibited?
The Ministry of Health and Family Welfare issued notifications prohibiting 16 Fixed Dose Combinations for human use with immediate effect.
The prohibition covers:
Manufacture
Sale
Distribution
of these combinations across India.
The decision follows recommendations from:
Subject Expert Committees (SECs)
Drugs Technical Advisory Board (DTAB)
The Expert Committees determined that these specific products lack therapeutic justification, present an unfavorable benefit-to-risk ratio, and are superseded by safer, more effective monotherapies or rational alternatives already in the clinical pipeline.
Lacks therapeutic justification
Are irrational
Offer an unfavorable benefit-risk profile
Have safer alternatives already available
The prohibited combinations include:
Acetyl Salicylic Acid + Ethoheptazine
Aloe Vera + Jojoba Oil + Wheat Germ Oil + Tea Tree Oil
Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes
Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide
Amoxicillin + Serratiopeptidase
Aloe Extract + Allantoin + Alpha Tocopherol Acetate + D-Panthenol + Vitamin A
Aloe Extract + Vitamin E + Dimethicone + Glycerine
Aloe Vera + Jojoba Oil + Vitamin E
Aloe Vera + Orange Oil
Aloe Vera + Vitamin E + Herbal Preparation
Aloe Vera + Tea Tree Oil
Aloe Vera + Vitamin E + Tea Tree Oil
Aloe Vera + Wheat Germ Oil + Tea Tree Oil
Aloe Vera + Jojoba Oil + Olive Oil + Vitamin E
Aloe Vera + Vitamin E + Olive Oil
Aloe Vera + Olive Oil
The ban heavily targets topical dermatological preparations and enzymatic combinations where the clinical superiority of the multi-drug format has not been substantiated by robust data. The Government of India's prohibition of 16 Fixed Dose Combinations (FDCs) represents more than the withdrawal of a few pharmaceutical products; it reinforces the country's commitment to evidence-based medicine and rational drug therapy.
Following a detailed scientific evaluation by the Subject Expert Committees (SECs) and the Drugs Technical Advisory Board (DTAB), the Ministry of Health & Family Welfare concluded that these combinations lacked adequate therapeutic justification, failed to demonstrate meaningful clinical superiority, or exposed patients to unnecessary risks. While the affected products belong to different therapeutic categories, they share a common regulatory concern: their benefits did not sufficiently outweigh their risks when compared with existing single-drug therapies or rational combinations.
The prohibited formulations can be broadly classified into five categories.
1. Amoxicillin + Serratiopeptidase
What is this combination?
This formulation combines Amoxicillin, a broad-spectrum penicillin antibiotic used to treat bacterial infections, with Serratiopeptidase, a proteolytic enzyme promoted for reducing inflammation and tissue swelling.
The combination was commonly prescribed for respiratory tract infections, dental infections, ENT disorders, and post-operative inflammatory conditions.
How was it intended to work?
The therapeutic concept was straightforward:
Amoxicillin eliminates the bacterial infection by inhibiting bacterial cell wall synthesis.
Serratiopeptidase was expected to reduce inflammation, improve tissue penetration of the antibiotic, relieve pain, and accelerate healing.
Manufacturers promoted the combination as providing both infection control and symptomatic relief in a single dosage form.
Why was it prohibited?
The expert committees found insufficient high-quality clinical evidence demonstrating that adding Serratiopeptidase produced better clinical outcomes than Amoxicillin alone.
Specifically, there was no convincing evidence showing improvements in:
Faster bacterial eradication
Shorter recovery time
Reduced complications
Improved cure rates
Instead, the combination increased treatment complexity and medication exposure without delivering measurable therapeutic benefits.
From a regulatory perspective, antibiotics should be prescribed only with medicines that have a clearly established scientific rationale. Including an additional enzyme without proven efficacy conflicts with the principles of rational antibiotic use and antimicrobial stewardship, both of which aim to minimize unnecessary drug exposure and reduce antimicrobial resistance (AMR).
2. Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes
What is this combination?
This three-component FDC combines:
Amoxicillin – Antibiotic
Serratiopeptidase – Anti-inflammatory enzyme
Lactobacillus Sporogenes – Probiotic
The formulation attempted to address bacterial infection, inflammation, and antibiotic-associated gastrointestinal disturbances simultaneously.
How was it intended to work?
The proposed therapeutic rationale was that:
Amoxicillin would eliminate the infection.
Serratiopeptidase would reduce inflammation and tissue swelling.
Lactobacillus Sporogenes would restore the intestinal microbiota disrupted by antibiotic therapy.
By combining all three agents into a single dosage form, manufacturers positioned the product as a comprehensive treatment.
Why was it prohibited?
Although each ingredient has an independent therapeutic role, regulators concluded that combining them into a fixed-dose product lacked scientific justification.
Every patient receiving an antibiotic does not necessarily require:
anti-inflammatory enzyme therapy, or
probiotic supplementation.
A fixed-dose combination removes physicians' ability to tailor treatment according to individual clinical needs, resulting in unnecessary polypharmacy.
Moreover, no robust evidence demonstrated that administering these three agents together produced superior outcomes compared with prescribing each medicine separately when clinically indicated.
3. Acetyl Salicylic Acid (Aspirin) + Ethoheptazine
What is this combination?
This FDC combines:
Acetyl Salicylic Acid (Aspirin) analgesic, antipyretic, anti-inflammatory, and antiplatelet agent.
Ethoheptazine is an opioid-like analgesic historically used for moderate pain.
How was it intended to work?
The formulation attempted to provide enhanced pain relief by combining two analgesics acting through different pharmacological mechanisms.
In theory, this approach could improve pain management by producing additive analgesic effects.
Why was it prohibited?
Regulatory review found no convincing evidence that Ethoheptazine significantly enhanced pain relief beyond what Aspirin could already provide.
Instead, the combination increased the likelihood of:
gastrointestinal irritation,
central nervous system adverse effects,
unnecessary opioid exposure.
Given the availability of safer, more effective analgesic options, the overall benefit-risk profile was deemed unfavourable.
4. Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide
What is this combination?
This four-drug FDC includes:
Ingredient | Therapeutic Role |
Dicyclomine | Antispasmodic |
Paracetamol | Analgesic & Antipyretic |
Clidinium Bromide | Anticholinergic |
Chlordiazepoxide | Benzodiazepine Anxiolytic |
The combination was marketed for gastrointestinal disorders associated with abdominal pain, spasms, and anxiety.
How was it intended to work?
The formulation aimed to provide multiple therapeutic actions simultaneously by:
relieving abdominal spasms,
reducing pain,
decreasing gastrointestinal secretions,
controlling anxiety associated with digestive disorders.
Why was it prohibited?
The principal concern was the routine inclusion of Chlordiazepoxide.
Benzodiazepines are associated with:
sedation,
cognitive impairment,
dependence,
misuse potential.
Not every patient experiencing gastrointestinal discomfort requires anxiolytic therapy. A fixed-dose formulation forces all patients, including those without anxiety, to receive a psychotropic medicine unnecessarily.
The combination also restricts physicians' ability to individualize therapy and increases the likelihood of adverse drug reactions.
5. Aloe Vera-Based Dermatological Combinations
What are these combinations?
The remaining eleven prohibited FDCs consist primarily of topical formulations containing combinations of:
Aloe Vera / Aloe Extract
Vitamin E
Tea Tree Oil
Olive Oil
Jojoba Oil
Wheat Germ Oil
Orange Oil
Allantoin
D-Panthenol
Glycerine
Herbal preparations
These products were marketed for wound healing, skin moisturization, burns, dry skin, and dermatological care.
How were they intended to work?
Each ingredient contributes different skin-conditioning properties:
Aloe Vera provides soothing and moisturizing effects.
Vitamin E functions as an antioxidant.
Tea Tree Oil offers mild antimicrobial activity.
Olive Oil and Jojoba Oil improve skin hydration.
Allantoin and D-Panthenol promote epithelial repair and skin barrier restoration.
Manufacturers claimed that combining these ingredients would provide enhanced therapeutic performance.
Why were they prohibited?
The concern was not the individual ingredients themselves, many of which are widely accepted in cosmetic and skincare products.
Rather, regulators found that manufacturers had not demonstrated:
clinically meaningful synergistic effects,
superior therapeutic outcomes,
improved patient benefit,
adequate scientific evidence supporting medicinal claims.
Simply combining multiple natural ingredients does not automatically create a rational medicine. Every medicinal FDC must demonstrate therapeutic necessity, efficacy, safety, and clinical superiority over existing alternatives.
The Scientific and Regulatory Basis for the Prohibition
Although the prohibited formulations vary significantly, the Government's decision was guided by four fundamental regulatory principles.
1. Lack of Therapeutic Justification
Every active pharmaceutical ingredient included in an FDC must make a meaningful contribution to patient outcomes. Several prohibited formulations failed to demonstrate additive efficacy, pharmacological synergy, or improved clinical performance over individual medicines. Without clear therapeutic justification, combining multiple APIs merely increases treatment complexity without improving healthcare outcomes.
2. Increased Risk Without Additional Benefit
Each additional ingredient introduces the possibility of adverse reactions, drug interactions, allergic responses, medication errors, and increased treatment costs. When similar clinical outcomes can be achieved using fewer medicines, unnecessary combinations expose patients to avoidable risks without delivering proportional benefits.
3. Promoting Rational Antibiotic Use
The prohibition of Amoxicillin-based combinations aligns with India's efforts to strengthen antimicrobial stewardship. Antibiotics should be prescribed judiciously, and combinations lacking proven therapeutic value may contribute to inappropriate prescribing practices and the growing challenge of antimicrobial resistance (AMR). By eliminating irrational antibiotic combinations, regulators are reinforcing evidence-based infection management.
4. Evidence-Based Regulatory Decision Making
Modern pharmaceutical regulation is firmly rooted in scientific evidence. Manufacturers must demonstrate not only the safety and efficacy of individual ingredients but also the scientific rationale for combining them. Clinical efficacy, pharmacokinetic compatibility, pharmacodynamic synergy, stability, and an acceptable benefit-to-risk profile are all essential for regulatory approval. In the absence of such evidence, continued marketing of an FDC cannot be justified.
The Government exercised its powers under Section 26A of the Drugs and Cosmetics Act, 1940.
Section 26A is the Government's primary tool for safeguarding public interest. It allows the Central Government to bypass standard procedures to prohibit drugs that are found to be risky, therapeutically valueless, or irrational. This section has been the cornerstone of all major FDC clean-ups in the last decade.
the drug involves risk to human beings,
lacks therapeutic value,
contains ingredients without therapeutic justification,
Or such a prohibition is necessary in the public interest.
This provision has previously been used to prohibit numerous irrational FDCs, including the large-scale bans announced in 2016 and subsequent years after judicial review and expert re-evaluation.
How Does CDSCO Evaluate Fixed Dose Combinations?
CDSCO's evaluation is an exhaustive process. To survive a review, an FDC must demonstrate pharmacological rationale, proven clinical efficacy, and flawless stability throughout its shelf life. Only those with a clearly superior benefit-to-risk profile remain authorized.
The assessment includes:
Pharmacological rationale
Does the combination make scientific sense?
Clinical efficacy
Has the combination demonstrated improved patient outcomes?
Safety profile
Are adverse effects acceptable?
Dose compatibility
Can both APIs be safely administered together?
Stability studies
Does the formulation remain chemically stable throughout shelf life?
Benefit-Risk Assessment
Do the benefits outweigh the risks?
Only after satisfying these requirements is regulatory approval granted.
Impact on Pharmaceutical Manufacturers
For manufacturers, this is a call for immediate operational recalibration. Affected companies must halt production lines, suspend distribution, and initiate stock withdrawals to avoid severe legal repercussions under the Drugs and Cosmetics Act.
Companies manufacturing these products must immediately:
Stop production.
Suspend distribution.
Withdraw stocks where applicable.
Notify supply chain partners.
Update product portfolios.
Ensure regulatory compliance.
Failure to comply could invite regulatory action under the Drugs and Cosmetics Act.
What About Contract Manufacturers and Third-Party Manufacturers?
CMOs cannot hide behind marketer requests. In the eyes of the regulator, the manufacturer is independently liable. Contract partners must proactively audit their portfolios and verify the approval status of every batch they produce. Every manufacturer remains independently responsible for regulatory compliance.
Companies should:
Review all manufacturing licenses.
Verify product approval status.
Monitor Gazette notifications.
Conduct periodic regulatory audits.
Maintain updated regulatory intelligence systems.
Impact on Doctors, Pharmacists, and Retailers
Healthcare professionals are the gatekeepers of this transition. Doctors must shift patients to rational alternatives, while pharmacists and retailers must purge their inventory of prohibited stocks to ensure no banned drug reaches a patient.
Doctors should:
Transition patients to rational alternatives.
Avoid prescribing prohibited combinations.
Pharmacists should:
Stop dispensing banned products.
Guide patients toward approved alternatives.
Monitor inventory.
Retailers must remove prohibited products from sale immediately.
What Does This Mean for Patients?
The goal isn't to disrupt therapy but to enhance it. Patients using these medicines should consult their physicians to transition to evidence-based, single-ingredient, or rational combination treatments that offer better safety margins.
Healthcare professionals can recommend:
alternative formulations,
single-ingredient products,
rational approved combinations,
evidence-based treatment options.
The objective of the prohibition is not to reduce treatment options but to ensure patients receive safer and more effective medicines.
Strengthening India's Regulatory Landscape
This ban is part of a larger trend toward global harmonization. India is strengthening its post-marketing surveillance and risk-based inspections to build international confidence in the "Pharmacy of the World."
stronger pharmacovigilance,
enhanced post-marketing surveillance,
risk-based inspections,
evidence-driven approvals,
harmonization with global regulatory expectations.
India continues to improve the quality and credibility of medicines manufactured within the country, strengthening confidence among domestic and international stakeholders.
Lessons for Pharmaceutical Companies
The takeaway for the industry is clear: invest in regulatory intelligence, prioritize scientific rationale over market trends, and maintain ironclad documentation for every product in your portfolio.
Invest in Regulatory Intelligence: Regulations evolve continuously. Companies should proactively monitor notifications issued by CDSCO and the Ministry of Health and Family Welfare.
Build Evidence-Based Product Portfolios: Commercial viability should never replace scientific justification.
Prioritize Pharmacovigilance: Continuous monitoring of marketed products helps identify emerging safety concerns before regulatory intervention becomes necessary.
Conduct Portfolio Reviews: Regular assessment of existing formulations helps identify products vulnerable to future regulatory changes.
Strengthen Documentation: Maintain complete dossiers supporting:
rationale,
safety,
efficacy,
stability,
regulatory approvals.
Why Regulatory Compliance Matters More Than Ever
Compliance is no longer a checkbox; it is a competitive advantage. Global partners now select manufacturers based on their inspection history, GMP consistency, and scientific depth. Global customers increasingly evaluate partners based on:
regulatory readiness,
documentation quality,
inspection history,
GMP compliance,
product lifecycle management,
scientific expertise.
Choosing a manufacturer with robust regulatory systems significantly reduces business risk.
Why Walter Healthcare?
At Walter Healthcare, we don't just manufacture; we validate. Our WHO-GMP compliant facilities and dedicated regulatory teams ensure that every product we develop is built on a foundation of scientific integrity and evolving global standards. From robust stability data to comprehensive dossier support, we help our partners navigate the complex regulatory waters with confidence. Our comprehensive quality and regulatory framework includes:
Regulatory-Driven Product Development: Every formulation is assessed for scientific rationale, therapeutic relevance, and compliance with current regulatory guidelines before commercialization.
WHO-GMP Compliant Manufacturing: Our manufacturing facilities operate under stringent Good Manufacturing Practices (GMP), ensuring consistent product quality, safety, and traceability.
Comprehensive Quality Assurance: From raw material qualification and in-process controls to finished product testing, every batch undergoes rigorous quality evaluation aligned with pharmacopoeial and regulatory requirements.
Regulatory Documentation Support: Walter Healthcare provides complete technical documentation, including product dossiers, stability data, Certificates of Analysis (CoA), validation documents, and other regulatory records required for domestic and export markets.
Continuous Regulatory Surveillance: Our regulatory affairs team actively monitors updates issued by the Ministry of Health & Family Welfare, CDSCO, and international regulatory agencies, enabling timely portfolio reviews and compliance actions.
Custom Manufacturing with Compliance at the Core Whether developing new formulations or manufacturing for private labels, we work closely with our partners to ensure products remain scientifically justified, market-ready, and compliant throughout their lifecycle. By combining technical expertise with a proactive regulatory approach, Walter Healthcare helps clients reduce compliance risks, maintain uninterrupted market access, and build long-term confidence among healthcare professionals and patients.
Conclusion
The prohibition of these 16 FDCs is a milestone for rational therapy in India. It reminds us that regulatory compliance is a marathon, not a sprint. Organizations that prioritize quality and clinical evidence today will be the leaders of the pharmaceutical industry tomorrow. For pharmaceutical manufacturers, marketers, and healthcare professionals, this notification serves as a reminder that regulatory compliance is a continuous process rather than a one-time approval. Regular portfolio reviews, evidence-based product development, robust pharmacovigilance, and proactive regulatory intelligence are now indispensable for sustainable growth in the pharmaceutical sector. As India's regulatory environment continues to evolve in line with global standards, organizations that prioritize scientific rigor, quality assurance, and compliance will be better positioned to earn the trust of regulators, healthcare providers, and patients alike. Partnering with experienced manufacturers such as Walter Healthcare can help businesses navigate these evolving expectations while delivering medicines that meet the highest standards of quality, safety, and efficacy.
Comments